Zhitong Finance App News, Federal Pharmaceuticals (03933.HK) announced that the Class 1 innovative drug UBT251 injection independently developed by the Company's wholly-owned subsidiary Federal Biotechnology (Zhuhai Hengqin) Co., Ltd. (“Federal Biotechnology”) has completed administration to participants in the first phase III clinical study of type 2 diabetes in China. This study will conduct two studies, “UNIGUIDE-1” and “UNIGUIDE-2,” respectively.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.